Latest Headlines
-
Nuclera And Cytiva Join Forces To Accelerate Drug Discovery
5/28/2025
At Nuclera, we’re driven by a single goal: to revolutionize protein expression and optimization. That’s why we’re excited to share news of our latest collaboration with Cytiva, a global leader in life sciences.
-
Radyus Research And Eurofins CDMO Alphora Announce Strategic Partnership To Accelerate And Optimize Drug Development
5/28/2025
Radyus Research, a U.S.-based drug development organization, and Eurofins CDMO Alphora, a Canadian contract development and manufacturing organization announced a new strategic partnership to help accelerate early-stage drug development for biotech companies worldwide.
-
Nuclera And Cytiva Collaborate To Accelerate Characterization Of Proteins For Drug Development
5/28/2025
Nuclera, the biotechnology company accelerating protein expression and optimization through its benchtop eProtein Discovery System, has announced a collaboration with Cytiva, a global life sciences leader.
-
Selvita Acquires License For Medicines Discovery Catapult's Patented Target Engagement Technology
5/27/2025
Selvita is the first contract research organisation (CRO) to license a Chemical Protein Stability Assay developed and patented by Medicines Discovery Catapult (MDC) to help identify and prioritise drug candidates faster.
-
GSK's Depemokimab Accepted For Review By Health Canada For The Treatment Of Asthma With Type 2 Inflammation And For Chronic Rhinosinusitis With Nasal Polyps
5/26/2025
GSK has submitted a New Drug Submission (NDS) to Health Canada for depemokimab for two proposed indications: The first indication is as an add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterized by an eosinophilic phenotype on medium- to high-dose inhaled corticosteroids (ICS) plus another asthma controller.
-
Siegfried Expands Production Capacity For Ophthalmic Drugs In El Masnou
5/23/2025
Siegfried, a leading global Contract Development and Manufacturing Organization (CDMO) for the pharmaceutical industry, today announced a further expansion of its ophthalmic drug manufacturing site in El Masnou near Barcelona, Spain.
-
Global Summit On Microphysiological Systems Research Set To Shape The Future Of Drug Development And Disease Modeling
5/22/2025
The 4th Annual MPS World Summit, hosted by the International MPS Society (IMPSS) and supported by EUROoCS, will take place in Brussels, Belgium this summer.
-
Avenzo Therapeutics Announces FDA Clearance Of Investigational New Drug Application For AVZO-1418, A Potential Best-In-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate
5/22/2025
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-1418 (DB-1418), a potential best-in-class, novel EGFR/HER3 bispecific antibody-drug conjugate (ADC).
-
GATC Health Paper Quantifies AI-Driven Capital Efficiencies And Advances Human-Centered Drug Discovery
5/22/2025
GATC Health Corp, a leading tech-bio company leveraging artificial intelligence (AI) to transform drug discovery, has published a new paper, AI in Drug Development: Advancing Capital Efficiency, Reducing Animal Testing, and Driving Precision Medicine.
-
Sanofi To Acquire Vigil Neuroscience, Inc., Adding A New Investigational Medicine To Treat Alzheimer's Disease To The Neurology Pipeline
5/21/2025
Sanofi announced today that it has entered into an agreement to acquire Vigil Neuroscience, Inc. (“Vigil”), a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases.